TABLE 1.
Characteristics of patients used for sample collection for various experiments
| Patient ID | Age (yr) | Sex | Medical condition | Procedure | Tissue | Material | Experiment | Data in |
|---|---|---|---|---|---|---|---|---|
| P12-006 | 21 | Female | ACLT | ACL-R | ACL | Tissues | Real-time PCR | Fig. 1 |
| P12-009 | 28 | Male | ACLT | ACL-R | ACL | Tissues | Real-time PCR | Fig. 1 |
| P12-011 | 26 | Male | ACLT | ACL-R | ACL | Tissues | Real-time PCR | Fig. 1 |
| P12-018 | 14 | Female | ACLT | ACL-R | ACL | Tissues | Real-time PCR | Fig. 1 |
| P12-022 | 19 | Female | ACLT | ACL-R | ACL | Tissues | Real-time PCR | Fig. 1 |
| P12-024 | 32 | Male | ACLT | ACL-R | ACL | Tissues | Real-time PCR | Fig. 1 |
| P12-003 | 15 | Female | ACLT | ACL-R | ACL | Tissues | Real-time PCR | Fig. 1 |
| P12-012 | 32 | Male | ACLT | ACL-R | ACL | Tissues | Real-time PCR | Fig. 1 |
| P12-021 | 39 | Male | ACLT | ACL-R | ACL | Tissues | Real-time PCR | Fig. 1 |
| P12-025 | 33 | Male | ACLT | ACL-R | ACL | Tissues | Real-time PCR | Fig. 1 |
| P12-029 | 18 | Male | ACLT | ACL-R | ACL | Tissues | Real-time PCR | Fig. 1 |
| P12-032 | 40 | Female | ACLT | ACL-R | ACL | Tissues | Real-time PCR | Fig. 1 |
| S1-2M | 59 | Female | OA | TKA | Cartilage | Tissues | Real-time PCR | Fig. 1 |
| S1-3M | 52 | Male | OA | TKA | Cartilage | Tissues | Real-time PCR | Fig. 1 |
| S1-8M | 57 | Female | OA | TKA | Cartilage | Tissues | Real-time PCR | Fig. 1 |
| S1-9M | 66 | Female | OA | TKA | Cartilage | Tissues | Real-time PCR | Fig. 1 |
| S1-10M | 71 | Female | OA | TKA | Cartilage | Tissues | Real-time PCR | Fig. 1 |
| S1-11M | 65 | Male | OA | TKA | Cartilage | Tissues | Real-time PCR | Fig. 1 |
| S1-14M | 56 | Female | OA | TKA | Cartilage | Tissues | Real-time PCR | Fig. 1 |
| S1-16M | 61 | Male | OA | TKA | Cartilage | Tissues | Real-time PCR | Fig. 1 |
| P15-035 | 40 | Female | ACLT | ACL-R | ACL | Cells | Immunostaining | Fig. 2 |
| P15-036 | 37 | Male | ACLT | ACL-R | ACL | Cells | Immunostaining | Fig. 2 |
| P15-037 | 51 | Female | ACLT | ACL-R | ACL | Cells | Immunostaining | Fig. 2 |
| CS244 | 65 | Male | OA | TKA | Cartilage | Cells | Immunostaining | Fig. 2 |
| CS245 | 52 | Female | OA | TKA | Cartilage | Cells | Immunostaining | Fig. 2 |
| CS246 | 60 | Female | OA | TKA | Cartilage | Cells | Immunostaining | Fig. 2 |
| P15-004 | 19 | Female | ACLT | ACL-R | ACL | Cells | Real-time PCR | Fig. 3 |
| P15-005 | 14 | Male | ACLT | ACL-R | ACL | Cells | Real-time PCR | Fig. 3 |
| P15-006 | 32 | Male | ACLT | ACL-R | ACL | Cells | Real-time PCR | Fig. 3 |
| P15-007 | 33 | Male | ACLT | ACL-R | ACL | Cells | Real-time PCR | Fig. 3 |
| P15-009 | 63 | Female | ACLT | ACL-R | ACL | Cells | Real-time PCR | Fig. 3 |
| P15-011 | 18 | Male | ACLT | ACL-R | ACL | Cells | Real-time PCR | Fig. 3 |
| CS-203 | 63 | Male | OA | TKA | Cartilage | Cells | Real-time PCR | Fig. 3 |
| CS-204 | 64 | Female | OA | TKA | Cartilage | Cells | Real-time PCR | Fig. 3 |
| CS-67 | 67 | Female | OA | TKA | Cartilage | Cells | Real-time PCR | Fig. 3 |
| CS-76 | 81 | Female | OA | TKA | Cartilage | Cells | Real-time PCR | Fig. 3 |
| CS-139 | 53 | Female | OA | TKA | Cartilage | Cells | Real-time PCR | Fig. 3 |
| CS-140 | 60 | Male | OA | TKA | Cartilage | Cells | Real-time PCR | Fig. 3 |
| CS-195 | 62 | Male | OA | TKA | Cartilage | Cells | Real-time PCR | Fig. 3 |
| CS-201 | 63 | Female | OA | TKA | Cartilage | Cells | Real-time PCR | Fig. 3 |
| CS-202 | 64 | Female | OA | TKA | Cartilage | Cells | Real-time PCR | Fig. 3 |
| P15-051 | 16 | Male | ACLT | ACL-R | ACL | Cells | Cell adhesion assay | Fig. 8 |
| P15-053 | 17 | Female | ACLT | ACL-R | ACL | Cells | Cell adhesion assay | Fig. 8 |
| P15-058 | 23 | Male | ACLT | ACL-R | ACL | Cells | Cell adhesion assay | Fig. 8 |
| CS271 | 69 | Female | OA | TKA | Cartilage | Cells | Cell adhesion assay | Fig. 8 |
| CS272 | 79 | Male | OA | TKA | Cartilage | Cells | Cell adhesion assay | Fig. 8 |
| CS273 | 54 | Male | OA | TKA | Cartilage | Cells | Cell adhesion assay | Fig. 8 |
| P15-030 | 15 | Female | ACLT | ACL-R | ACL | Cells | RNA-seq validation | Fig. 9 |
| P15-041 | 38 | Male | ACLT | ACL-R | ACL | Cells | RNA-seq validation | Fig. 9 |
| P15-044 | 15 | Male | ACLT | ACL-R | ACL | Cells | RNA-seq validation | Fig. 9 |
| P15-047 | 26 | Female | ACLT | ACL-R | ACL | Cells | RNA-seq validation | Fig. 9 |
| P15-048 | 44 | Male | ACLT | ACL-R | ACL | Cells | RNA-seq validation | Fig. 9 |
| CS67 | 67 | Female | OA | TKA | Cartilage | Cells | RNA-seq validation | Fig. 9 |
| CS76 | 81 | Female | OA | TKA | Cartilage | Cells | RNA-seq validation | Fig. 9 |
| CS139 | 53 | Female | OA | TKA | Cartilage | Cells | RNA-seq validation | Fig. 9 |
| CS140 | 60 | Male | OA | TKA | Cartilage | Cells | RNA-seq validation | Fig. 9 |
| CS195 | 62 | Male | OA | TKA | Cartilage | Cells | RNA-seq validation | Fig. 9 |
| CS201 | 63 | Female | OA | TKA | Cartilage | Cells | RNA-seq validation | Fig. 9 |
| P15-057 | 20 | Female | ACLT | ACL-R | ACL | Cells | Isoform 1 overexpression | Fig. 10 |
| P15-058 | 23 | Male | ACLT | ACL-R | ACL | Cells | Isoform 1 overexpression | Fig. 10 |
| P15-059 | 19 | Male | ACLT | ACL-R | ACL | Cells | Isoform 1 overexpression | Fig. 10 |
| P15-051 | 16 | Male | ACLT | ACL-R | ACL | Cells | POSTN siRNA | Fig. 11 |
| P15-053 | 17 | Female | ACLT | ACL-R | ACL | Cells | POSTN siRNA | Fig. 11 |
| P15-056 | 50 | Female | ACLT | ACL-R | ACL | Cells | POSTN siRNA | Fig. 11 |
| P15-061 | 48 | Male | ACLT | ACL-R | ACL | Cells | POSTN siRNA | Fig. 11 |
| P15-062 | 41 | Female | ACLT | ACL-R | ACL | Cells | POSTN siRNA | Fig. 11 |
ACLT, ACL tear; ACL-R, ACL reconstruction; TKA, total knee arthroplasty.